TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6139572

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP) administered intravenously at 6 pmol/kg/min for 15 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP)
Number of subjects: 7
Study: 31797034

Group type: EXPERIMENTAL
Intervention: CIU + PA
Number of subjects: 10

Group type: COMPARATOR
Intervention: CIU control
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 10
Study: 31494615

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously
Number of subjects: 8880

Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8880
Study: 27684419

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive pressure (nCPAP)
Number of subjects: 0
Study: 25990255

Group type: EXPERIMENTAL
Intervention: 1 mmol/kg of KHCO3 daily for 3 months
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 1.5 mmol/kg of KHCO3 daily for 3 months
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 24483776

Group type: EXPERIMENTAL
Intervention: Self-reported recall of weight monitoring adherence (daily or more frequent weighing)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Diary-recorded weight monitoring adherence (≥80% of days)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (less frequent weight monitoring)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (diary-recorded adherence <80%)
Number of subjects: 216
Study: 23088945

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncontrast MR angiography
Number of subjects: 0
Study: 20581798

Group type: EXPERIMENTAL
Intervention: Lithium and divalproex
Number of subjects: 403
Study: 17714964

Group type: EXPERIMENTAL
Intervention: AH26 sealer and gutta‐percha
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resilon and Epiphany
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketac‐Endo Aplicap and gutta‐percha
Number of subjects: 60

Group type: COMPARATOR
Intervention: No obturation (Control group)
Number of subjects: 60
Study: 15848645

Group type: EXPERIMENTAL
Intervention: T-tube
Number of subjects: 84

Group type: COMPARATOR
Intervention: No T-tube
Number of subjects: 84
Study: 12074206

Group type: EXPERIMENTAL
Intervention: 15 mg pioglitazone
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 9806378

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study: 9098478

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in women Ct positive but affected by PID
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (Ct) positive
Number of subjects: 369
Study: 3728360

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight-loss diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 30218882

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT) delivered by physiotherapists
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 11
Study: 27239706

Group type: EXPERIMENTAL
Intervention: Girls First (combined psychosocial and health curriculum)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Health Curriculum (HC)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3000
Study: 24428466

Group type: EXPERIMENTAL
Intervention: 5 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 25 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 75 mg daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 400 mg weekly
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 23406994

Group type: EXPERIMENTAL
Intervention: MA (160 mg po, bid) plus thalidomide (50 mg po, bid)
Number of subjects: 102

Group type: COMPARATOR
Intervention: MA (160 mg po, bid) alone
Number of subjects: 102
Study: 21029594

Group type: EXPERIMENTAL
Intervention: Active γ‐IUD
Number of subjects: 1781

Group type: COMPARATOR
Intervention: G‐Cu200
Number of subjects: 1781

Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 1781
Study: 18507658

Group type: EXPERIMENTAL
Intervention: AMP challenge regimen A (08.00 h, repeated 24 h later)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AMP challenge regimen B (08.00 h, repeated 12 and 24 h later)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AMP challenge regimen C (20.00 h, repeated 12 h later)
Number of subjects: 26
Study: 19735557

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PfHRP2 RDT
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PfLDH test
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 205
Study: 15181652

Group type: EXPERIMENTAL
Intervention: Kava extract (300 mg; p.o.)
Number of subjects: 0
Study: 11814535

Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg)
Number of subjects: 14
Study: 9365359

Group type: EXPERIMENTAL
Intervention: Total contact casts with a cast heel (TCCH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total contact casts with a cast boot (TCCB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Therapeutic XtraDepth shoes (XDS)
Number of subjects: 40
Study: 8422824

Group type: EXPERIMENTAL
Intervention: Six small meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Two large meals
Number of subjects: 12
Study: 3568947

Group type: EXPERIMENTAL
Intervention: pirenzepine (PIR), 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propantheline (PRO), 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: cimetidine (CIM), 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine (RAN), 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bethanechol (BET), 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: metoclopramide (MET), 10 mg
Number of subjects: 12
Study: 30851253

Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Modified Nasal Hood
Number of subjects: 50
Study: 29764099

Group type: EXPERIMENTAL
Intervention: IsoLite® system (IL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional rubber dam (RD)
Number of subjects: 8
Study: 27064778

Group type: EXPERIMENTAL
Intervention: Lateral suprapatellar injection site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial infrapatellar injection site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral infrapatellar injection site
Number of subjects: 0
Study: 25039547

Group type: EXPERIMENTAL
Intervention: Vicryl Rapide
Number of subjects: 115

Group type: COMPARATOR
Intervention: Prolene
Number of subjects: 115
Study: 22682149

Group type: EXPERIMENTAL
Intervention: Blood volume-monitored regulation of ultrafiltration and dialysate conductivity (UCR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood volume-monitored regulation of ultrafiltration and temperature (UTR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (UCR, UTR, Conventional)
Number of subjects: 60
Study: 21155144

Group type: EXPERIMENTAL
Intervention: GDS₃₀
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GDS₁₅
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GDS₄(/)₅
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine clinical judgment
Number of subjects: 69
Study: 17975480

Group type: EXPERIMENTAL
Intervention: Nonselective beta‐adrenergic blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline hepatic venous pressure gradient >10 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reductions in hepatic venous pressure gradient >10%
Number of subjects: 0
Study: 15210375

Group type: EXPERIMENTAL
Intervention: Previous experiments involving compulsive washing and compulsive checking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New experiment involving compulsive ordering and arranging
Number of subjects: 0
Study: 11718169

Group type: EXPERIMENTAL
Intervention: Verteporfin + laser therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 0
Study: 9620921

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7988608

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure
Number of subjects: 132

Group type: COMPARATOR
Intervention: Patients without congestive heart failure
Number of subjects: 132
Study: 2921710

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 25
Study: 30248552

Group type: EXPERIMENTAL
Intervention: Digital vaginal examination and speculum insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foley catheter insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foley catheter in situ for a median of 14 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being overseas-born
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discomfort during speculum insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inserter designation or experience
Number of subjects: 0
Study: 28029063

Group type: EXPERIMENTAL
Intervention: Exergames intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 25448247

Group type: EXPERIMENTAL
Intervention: Conventional abdominal binder
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adjustable abdominal binder
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Maximal tolerable abdominal compression (conventional binder)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Maximal tolerable abdominal compression (adjustable binder)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Reduction of compression to tolerable levels (conventional binder)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Reduction of compression to tolerable levels (adjustable binder)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No abdominal compression (control)
Number of subjects: 13
Study: 24283167

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Subarachnoid Anesthesia (SA)
Number of subjects: 380
Study: 21533657

Group type: EXPERIMENTAL
Intervention: Radioguided seed localization (RSL)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 305
Study: 18281407

Group type: EXPERIMENTAL
Intervention: STEPPS plus treatment as usual
Number of subjects: 124

Group type: COMPARATOR
Intervention: treatment as usual alone
Number of subjects: 124
Study: 16537679

Group type: EXPERIMENTAL
Intervention: Metyrapone (MET)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metyrapone (MET) + Oral Hydrocortisone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Feeding condition (FED)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fasting condition (FAST)
Number of subjects: 13
Study: 12205648

Group type: EXPERIMENTAL
Intervention: Simvastatin (up to 80mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10353378

Group type: EXPERIMENTAL
Intervention: Right hand
Number of subjects: 18

Group type: COMPARATOR
Intervention: Left hand
Number of subjects: 18
Study: 7866800

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ice and elastic wrap
Number of subjects: 102
Study: 16296700

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7142740

Group type: EXPERIMENTAL
Intervention: Topical steroid formulated in a series of solutions and gels at 90% saturation
Number of subjects: 0
Study: 30975584

Group type: EXPERIMENTAL
Intervention: ∆9-tetrahydrocannabinol (THC)
Number of subjects: 39
Study: 28711318

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 1710

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1710
Study: 25944854

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Telmisartan (80 mg)
Number of subjects: 303
Study: 24338254

Group type: EXPERIMENTAL
Intervention: Fluticasone and Vitamin E (50mg/day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fluticasone plus placebo
Number of subjects: 240
Study: 22884593

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 20399

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 20399

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 20399

Group type: COMPARATOR
Intervention: Boys
Number of subjects: 20399
Study: 19552659

Group type: EXPERIMENTAL
Intervention: Ready-to-use fortified spread
Number of subjects: 336

Group type: COMPARATOR
Intervention: Corn/soy blended flour
Number of subjects: 336
Study: 17428017

Group type: EXPERIMENTAL
Intervention: 300 mg gabapentin capsule
Number of subjects: 24
Study: 15682770

Group type: EXPERIMENTAL
Intervention: African Americans (AA)
Number of subjects: 3204

Group type: COMPARATOR
Intervention: Caucasians (C)
Number of subjects: 3204
Study: 11462061

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: D-arginine
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2.0% saline
Number of subjects: 8
Study: 9160940

Group type: EXPERIMENTAL
Intervention: Prosthesis inserted without cement
Number of subjects: 139

Group type: COMPARATOR
Intervention: Prosthesis inserted with cement
Number of subjects: 139
Study: 7965151

Group type: EXPERIMENTAL
Intervention: Iodine-123-MIBG SPECT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Planar and SPECT combined
Number of subjects: 25
Study: 3602221

Group type: EXPERIMENTAL
Intervention: Unilateral ECT two times weekly
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unilateral ECT three times weekly
Number of subjects: 20
Study: 31808136

Group type: EXPERIMENTAL
Intervention: Post-ICH OAC use
Number of subjects: 1502
Study: 30740964

Group type: EXPERIMENTAL
Intervention: Combined oral medroxyprogesterone acetate (MPA) 500 mg/day / levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endometrial aspiration biopsy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dilatation & curettage (D&C)
Number of subjects: 44
Study: 28405743

Group type: EXPERIMENTAL
Intervention: Conventional technique for Pap smear (41 women)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Liquid-based cytology (40 women)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Inter-observer variability among cytopathologists
Number of subjects: 81
Study: 24759040

Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Lower-protein control diet (10-15 en% protein)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) in (pre)hypertensive subjects
Number of subjects: 420

Group type: COMPARATOR
Intervention: Lower-protein control diet (10-15 en% protein) in (pre)hypertensive subjects
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) after adjustment for initial BP
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: High-protein diet (23-28 en% protein) after adjustment for weight change
Number of subjects: 420
Study: 23399553

Group type: EXPERIMENTAL
Intervention: Fluticasone 440 mcg twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 42
Study: 20574056

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjective sleep measures
Number of subjects: 24
Study: 19514651

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix 0.25 mg)
Number of subjects: 40
Study: 16741040

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (age- and sex-matched normal subjects)
Number of subjects: 29
Study: 15578258

Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10940698

Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m² i.v.) every 3 weeks plus medroxy progesterone acetate (MPA) 500 mg orally twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epirubicin alone
Number of subjects: 26
Study: 9051395

Group type: EXPERIMENTAL
Intervention: Asymmetric biphasic stimulation (A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (very low levels of stimulation current (MC) and no electrical stimulation (C))
Number of subjects: 80
Study: 8335504

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg for one day
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg for two days
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Fleroxacin (both regimens)
Number of subjects: 195
Study: 3720211

Group type: EXPERIMENTAL
Intervention: Minibag group (50- and 100-mL minibags of 5% dextrose injection or 0.9% sodium chloride injection)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Syringe group (20- and 50-mL quantities of sterile water for injection or 0.45% sodium chloride injection in plastic syringes)
Number of subjects: 93
Study: 3341253

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention (average loss of 12.3 kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 68
Study: 30962676

Group type: EXPERIMENTAL
Intervention: BAY 81-8973
Number of subjects: 44

Group type: COMPARATOR
Intervention: rFVIII-FS
Number of subjects: 44

Group type: COMPARATOR
Intervention: rAHF-PFM
Number of subjects: 44
Study: 28850308

Group type: EXPERIMENTAL
Intervention: Curcumin 250 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25346376

Group type: EXPERIMENTAL
Intervention: Pillar implant
Number of subjects: 29
Study: 24139250

Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine (buffered with 0.18 mL 8.4% sodium bicarbonate)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonbuffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 81
Study: 21655195

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 71

Group type: COMPARATOR
Intervention: Men
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both men and women
Number of subjects: 71
Study: 19536884

Group type: EXPERIMENTAL
Intervention: PF‐3512676 40 mg + DTIC (850 mg/m(2))
Number of subjects: 184

Group type: COMPARATOR
Intervention: DTIC (850 mg/m(2)) alone
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PF‐3512676 10 mg
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PF‐3512676 40 mg
Number of subjects: 184
Study: 16770284

Group type: EXPERIMENTAL
Intervention: 1000 kcal daily intravenous supplement for 3 days, followed by a 400 kcal oral nutritional supplement for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ordinary hospital food and beverage
Number of subjects: 80
Study: 15316335

Group type: EXPERIMENTAL
Intervention: PEG‐INF + RBV
Number of subjects: 95

Group type: COMPARATOR
Intervention: INF + RBV
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 95
Study: 11535845

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with a mixture of bupivacaine and fentanyl
Number of subjects: 42

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with intravenous morphine
Number of subjects: 42
Study: 9433593

Group type: EXPERIMENTAL
Intervention: Multipoint linkage analysis using highly deviant concordant and discordant independent sib pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkage analysis on adjusted quantitative variables
Number of subjects: 0
Study: 8300887

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 109

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 109
Study: 2882083

Group type: EXPERIMENTAL
Intervention: Bovine surfactant ('Surfactant TA') 100 mg/kg surfactant phospholipid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bovine surfactant ('Surfactant TA')
Number of subjects: 30
Study: 28549161

Group type: EXPERIMENTAL
Intervention: Extended Innovative System Intervention (E‐ISI)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard Treatment Control (STC)
Number of subjects: 175
Study: 26872889

Group type: EXPERIMENTAL
Intervention: Daclatasvir and asunaprevir
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (patients without renal dysfunction)
Number of subjects: 28